Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 - -- Expects to initiate global Phase 1/2 MAD clinical study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback